Nicolás, DavidSuárez, AntonioAmbrosioni, JuanManzardo, ChristianLigero, CarmenCosta, JosepFernández, EmmaMarcos, Ma. AngelesPlana Prades, MontserratMosquera, Maria MarSánchez-Palomino, SonsolesGatell, José M.Miró Meda, José M. (José María), 1956-2020-05-192020-05-192019-08-031201-9712https://hdl.handle.net/2445/161478Background: Severe cases of primary HIV infection have been described in patients presenting with neurological involvement, AIDS defining events or other life-threatening events. These severe forms have not been fully studied. Objectives: To determine the prevalence and characteristics of severe PHI in a hospital-based cohort of primary HIV infection, and the response to the early initiation of antiretroviral therapy (ART) at 12 months. Methods: Every patient with PHI attending Hospital Clínic of Barcelona (1997-2015) was evaluated. Severe PHI was defined using clinical, analytical and immunological criteria. Chi-squared test was used for categorical variables and Student's t-test for quantitative variables. Results: 33% of 224 PHI patients (95% CI: 26.84%-39.16%) had a severe PHI. These patients had more symptoms, abnormal analytical parameters and hospital admissions. The severe PHI group had a significantly higher viral load although no differences were observed at 12 months in terms of viral suppression or CD4 count recovery. None died during PHI. Conclusions: Up to one third of patients in our cohort presented with a severe PHI, which was associated with higher hospitalization rates and higher plasma HIV RNA viral load. However, severe forms were not associated to a worse clinical, immunological or virological outcome at 12 months.7 p.application/pdfengcc-by-nc-nd (c) Nicolás, David et al., 2019http://creativecommons.org/licenses/by-nc-nd/3.0/esInfeccions per VIHPacients amb lesions cerebralsAntiretroviralsHIV infectionsBrain damage patientsAntiretroviral agentsinfo:eu-repo/semantics/article6918922020-05-19info:eu-repo/semantics/openAccess